FDA Official Lists Four Regulatory Considerations For Connected Combination Products
CDRH’s Courtney Evans explained the four unique considerations that connected combination manufacturers products should assess when working with the US FDA.
You may also be interested in...
Electronic interface functionality, data-exchange factors and time synchronization are among key interoperability factors for device-makers to consider in device design and pre-market submissions, US FDA says in a final guidance document. The guidance stresses the need for developers to consider potential risks of interoperability from device conception and throughout the lifecycle.
The FDA sent a warning letter to Arbor Center for EyeCare for failing to submit an IND before beginning a trial of a novel drug-device combination product.
A color additive evaluation tool for polymeric medical devices was approved as an MDDT under the FDA’s voluntary program.